Genflow Biosciences PLC Announces Director Dealings

NYSE - LSE

CMSC	0.19%	21.03	$
BCC	0.62%	76.31	$
CMSD	0.05%	20.79	$
RIO	0.87%	102.75	$
GSK	-0.44%	50.44	$
BCE	-0.04%	23.4	$
BTI	-0.43%	55.68	$
BP	-1.23%	43.93	$
RBGPF	-3.2%	70	$
JRI	-0.75%	12.08	$
AZN	-0.52%	161.63	$
RELX	-1.56%	35.15	$
RYCEF	-0.15%	19.56	$
VOD	0.12%	16.07	$
NGG	-1.41%	78.05	$

Genflow Biosciences PLC Announces Director Dealings

BOULEVARD 28.03.2025

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Text size:

LONDON, UNITED KINGDOM / ACCESS Newswire / March 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") the only longevity company listed in Europe, is pleased to announce that it has been notified that Dr. Eric Leire, CEO of the Company, has today purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.

Details of the transaction are set out below:

Name	Dr. Eric Leire
Position	Chief Executive Officer
Date of Purchase	27 March 2025
Number of Ordinary Shares Purchased	2,100,000
Price per Ordinary Share	1.15p
Total Consideration	£24,150
Nature of Transaction	Market purchase
Total Shareholding Following the Transaction	126,514,999
Interest in Ordinary Shares (percentage)	36.18%

NOTIFICATION AND PUBLIC DISCLOSURE OF A TRANSACTION BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

The following disclosure is made in accordance with the requirements of the UK Market Abuse Regulation and provides details in relation to the purchase of Ordinary Shares by a Director:

Details of the person discharging managerial responsibilities / person closely associated

Name

Eric Leire

Reason for the Notification

Position/status

PDMR

Initial notification / Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Genflow Biosciences Plc

LEI

213800HVOFXRXVEGDN62

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the Financial instrument, type of instrument

Ordinary Shares of £0.0003

Identification Code

GB00BP2C3V08

Nature of the transaction

Issue of ordinary shares

Price(s) and volume(s)

Price(s)	Volume(s)
1.15pence per Ordinary Share	2,100,000 Ordinary Shares

Aggregated information:

 Aggregated volume

· Price

2,100,000 Ordinary Shares

1.15 pence per Ordinary Share

Dates of the transactions

27 March 2025

Place of the transactions

London

Contacts

Genflow Biosciences	Harbor Access
Dr Eric Leire, CEO	Jonathan Paterson, Investor Relations
+32-477-495-881	+1 475 477 9401
[email protected]

Corporate Brokers
Capital Plus Partners Ltd
Jon Critchley, +44 0203 821 6168

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Genflow Biosciences PLC

View the original press release on ACCESS Newswire

O.Ortiz--AT

Arizona Tribune - Genflow Biosciences PLC Announces Director Dealings

Genflow Biosciences PLC Announces Director Dealings

Featured

InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 03

Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity

US jury deadlocks again in Lindsay Clancy's child murder trial

Maltese tycoon acquitted of masterminding reporter's murder